SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
SpringWorks Therapeutics, Inc. (SWTX) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will be held in New York, New York, at 2:00 p.m. ET. The live webcast can be accessed on the company's website, with a replay available for a limited time after the conference.
01/31/2024 - 07:00 AM
STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, taking place in New York, New York on Thursday, February 8, 2024 at 2:00 p.m. ET.
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com . A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.
Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers. OGSIVEO™, approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is SpringWorks’ first FDA-approved therapy. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its lead product candidates into late-stage trials and enter into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.
For more information, visit www.springworkstx.com @SpringWorksTx LinkedIn YouTube
Contacts: kdiamond@springworkstx.com
Samantha Hilson Sandler samantha.sandler@springworkstx.com
When will SpringWorks Therapeutics participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference?
SpringWorks Therapeutics will participate in the conference on February 8, 2024.
Where will the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference take place?
The conference will take place in New York, New York.
What time will the fireside chat take place?
The fireside chat will take place at 2:00 p.m. ET.
How can the live webcast be accessed?
The live webcast can be accessed on the company's website.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available on SpringWorks' website for a limited time following the conference.
SpringWorks Therapeutics Inc
SWTX Rankings
#2681 Ranked by Stock Gains
SWTX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Stamford
About SWTX
springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.
